Biodesix, Inc.

NasdaqGM:BDSX 주식 리포트

시가총액: US$111.0m

Biodesix 경영진

경영진 기준 점검 2/4

Biodesix CEO는 Scott Hutton, Jan2020 에 임명되었습니다 의 임기는 6.33 년입니다. 총 연간 보상은 $2.24M, 28.7% 급여 및 71.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $535.47K 가치에 해당하는 회사 주식의 0.48% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 6 년과 6.2 년입니다.

핵심 정보

Scott Hutton

최고경영자

US$2.2m

총 보수

CEO 급여 비율28.74%
CEO 재임 기간6.3yrs
CEO 지분 보유율0.5%
경영진 평균 재임 기간6yrs
이사회 평균 재임 기간6.2yrs

최근 경영진 업데이트

It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year

May 14
It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year

Recent updates

BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upgraded Rating

Analysts have nudged their price target on Biodesix higher to $30.00 from $30, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and three consecutive quarters of execution above target as reasons for a more constructive view. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to an Outperform rating as a signal that recent execution and guidance support a higher valuation framework than before.

BDSX: Strong Guidance And Healthier Balance Sheet Will Support 2026 Momentum

Analysts have raised their price target on Biodesix from $30.00 to $56.14, citing 2026 revenue guidance that is 3% above prior expectations and a "significantly improved" balance sheet, with execution running above target for three consecutive quarters. Analyst Commentary Bullish Takeaways Bullish analysts point to the 2026 revenue guidance coming in 3% above prior expectations as support for a higher valuation range, given that it directly feeds into forward revenue estimates and P/S assumptions.

BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upside

Analysts have maintained their price target on Biodesix, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and what they see as three consecutive quarters of above target execution heading into 2026. Analyst Commentary The latest upgrade frames Biodesix as entering 2026 with momentum, supported by revenue guidance that sits 3% ahead of expectations and an improved balance sheet.

BDSX: Improved Balance Sheet And Guidance Will Support Momentum Into 2026

Analysts have reduced their price target on Biodesix from $35 to $30, citing updated fair value assumptions along with views that recent revenue guidance, improving margins, and a lower discount rate better reflect the company’s execution and balance sheet strength. Analyst Commentary Bullish Takeaways Bullish analysts point to the upgrade to an Outperform rating as a sign that recent execution and guidance are more in line with what they view as fair value.

BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability

Analysts have revised their price target on Biodesix to $40.00 from $40, reflecting updated views on discount rate, revenue growth, profit margin, and future P/E assumptions in their models. What's in the News Biodesix raised its revenue guidance for the fiscal year ending December 31, 2025, estimating total revenue of $88.5 million, above the previously increased range of $84 million to $86 million (company guidance).

BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability

Analysts have adjusted their price target on Biodesix to US$40.00 from US$40, citing updated assumptions around discount rates, revenue growth, profit margin, and future P/E that collectively refine, rather than overhaul, their previous view. What's in the News Biodesix issued new earnings guidance for the fourth quarter ended December 31, 2025, estimating total revenue of US$28.8 million for the period (Key Developments).

BDSX: Expanded Diagnostics Partnership Will Drive Revenue Upside In 2025

Analysts have increased their price target on Biodesix to reflect updated views on revenue growth potential and a slightly lower discount rate, while also adjusting expected profit margins and future P/E assumptions to align with their latest models. What's in the News Biodesix issued earnings guidance for the fourth quarter of 2025, estimating total revenue of $28.8 million for the period (Corporate guidance).

Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump

Jan 14
Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump

BDSX: Expanded Diagnostics Partnership And ESR1 Assay Rollout Will Drive Upside

Analysts have lifted their price target on Biodesix to US$20.00 from US$1.50, citing adjusted assumptions around revenue growth, profit margin, discount rate, and a lower future P/E multiple as the key drivers of this revised view. What's in the News Biodesix raised its fiscal 2025 revenue guidance and now expects total revenue between US$84 million and US$86 million for the year (Key Developments).

BDSX: Reverse Split And ATM Access Will Support Path To Profitability

Analysts have significantly lifted their price target on Biodesix from $2.00 to $40.00, citing updated models following the 20 for 1 reverse split, a reduced share count, and the company’s ability to utilize its at the market facility to support operations through an expected path to cash flow breakeven and profitability. Analyst Commentary Bullish analysts interpret the new price target framework as a constructive signal for Biodesix, emphasizing that the reset reflects mechanical impacts from the 20 for 1 reverse split rather than a fundamental deterioration in the business outlook.

Biodesix, Inc.'s (NASDAQ:BDSX) Shares Leap 27% Yet They're Still Not Telling The Full Story

Nov 29
Biodesix, Inc.'s (NASDAQ:BDSX) Shares Leap 27% Yet They're Still Not Telling The Full Story

US$32.50: That's What Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Is Worth After Its Latest Results

Nov 05
US$32.50: That's What Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Is Worth After Its Latest Results

It's Down 27% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Sep 18
It's Down 27% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Digital Integration And Expanded Lung Diagnostics Will Broaden Markets

The substantial increase in Biodesix’s consensus price target is accompanied by a modest improvement in forward earnings valuation and a slight rise in discount rate, indicating more favorable future expectations despite a marginally higher cost of capital, with fair value rising markedly to $35.00. What's in the News Biodesix announced a 1-for-20 stock split.

The Market Lifts Biodesix, Inc. (NASDAQ:BDSX) Shares 67% But It Can Do More

Jul 29
The Market Lifts Biodesix, Inc. (NASDAQ:BDSX) Shares 67% But It Can Do More

Biodesix, Inc. (NASDAQ:BDSX) Stock Rockets 30% But Many Are Still Ignoring The Company

Jun 14
Biodesix, Inc. (NASDAQ:BDSX) Stock Rockets 30% But Many Are Still Ignoring The Company

Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers

May 15
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers

It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year

May 14
It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year

Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding

Apr 19
Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding
User avatar

Sales Force Expansion And CLARIFY Study Will Boost Test Adoption

Expansion of sales force and test adoption, along with CLARIFY study results, are expected to drive revenue growth and improve margins.

It's Down 30% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Mar 05
It's Down 30% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

The Price Is Right For Biodesix, Inc. (NASDAQ:BDSX) Even After Diving 27%

Jan 19
The Price Is Right For Biodesix, Inc. (NASDAQ:BDSX) Even After Diving 27%

With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Nov 21
With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Sep 24
Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12
Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Mar 03
With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Jan 04
Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Jul 16
It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

CEO 보수 분석

Scott Hutton의 보수는 Biodesix의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Dec 31 2025US$2mUS$643k

-US$35m

Sep 30 2025n/an/a

-US$40m

Jun 30 2025n/an/a

-US$41m

Mar 31 2025n/an/a

-US$40m

Dec 31 2024US$2mUS$589k

-US$43m

Sep 30 2024n/an/a

-US$44m

Jun 30 2024n/an/a

-US$45m

Mar 31 2024n/an/a

-US$47m

Dec 31 2023US$2mUS$515k

-US$52m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$66m

Mar 31 2023n/an/a

-US$69m

Dec 31 2022US$3mUS$515k

-US$65m

Sep 30 2022n/an/a

-US$58m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$52m

Dec 31 2021US$5mUS$490k

-US$43m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$2mUS$364k

-US$31m

Sep 30 2020n/an/a

-US$33m

Jun 30 2020n/an/a

-US$34m

Mar 31 2020n/an/a

-US$33m

Dec 31 2019US$337kUS$298k

-US$31m

보상 대 시장: Scott의 총 보수(USD2.24M)는 US 시장에서 비슷한 규모 기업의 평균(USD623.53K)보다 높습니다.

보상과 수익: Scott의 보상은 회사가 적자임에도 증가했습니다.

CEO

Scott Hutton (53 yo)

6.3yrs
재임 기간
US$2,238,470
보수

Mr. Scott Hutton serves as President, Chief Executive Officer and Director at Biodesix, Inc. since January 1, 2020. He served as Chief Operating Officer at Biodesix, Inc. since March 2018 until December 20...

리더십 팀

이름직위재임 기간보수지분
Scott Hutton
President6.3yrsUS$2.24m0.48%
$ 535.5k
Robin Cowie
CFO, Secretary & Treasurer9.1yrsUS$962.00k0.16%
$ 178.2k
Kieran O'Kane
Chief Commercial Officer8.3yrsUS$1.01m0.097%
$ 107.8k
Heinrich Roder
Founder & CTOno data데이터 없음데이터 없음
Gary Pestano
Chief Scientific Officerless than a year데이터 없음0.10%
$ 113.7k
Jessica Olbricht
Senior Director of Human Resources2.3yrs데이터 없음데이터 없음
Bobbi Coffin
Chief Growth Officer6.2yrs데이터 없음데이터 없음
James Jett
Co-Chief Medical Officerno data데이터 없음데이터 없음
Steven Springmeyer
Co-Chief Medical Officer6yrs데이터 없음데이터 없음
Michael Kammer
Head of Radiomics1.3yrs데이터 없음데이터 없음
Christopher Vazquez
VP & Controller5.3yrs데이터 없음0.016%
$ 17.4k
6.0yrs
평균 재임 기간
50yo
평균 나이

경험이 풍부한 관리: BDSX의 경영진은 노련하고 경험이 풍부합니다(평균 재임 6 년).

이사회 구성원

이름직위재임 기간보수지분
Scott Hutton
President6.3yrsUS$2.24m0.48%
$ 535.5k
John Patience
Independent Chairman17.9yrsUS$26.87k0.25%
$ 277.9k
Jack Schuler
Independent Director17.9yrs데이터 없음22.89%
$ 25.4m
Hany Massarany
Independent Director5.8yrsUS$31.71k0.18%
$ 199.6k
Lair Kennedy
Independent Director3.3yrsUS$26.87k12.59%
$ 14.0m
Paul A. Bunn
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Matthew Strobeck
Independent Director14.3yrsUS$30.10k1.51%
$ 1.7m
John Kayyem
Independent Director4.4yrsUS$26.87k0.18%
$ 196.3k
David Carbone
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Craig Whitehouse
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Jean Franchi
Independent Director6.1yrsUS$33.32k0.053%
$ 59.4k
6.2yrs
평균 재임 기간
62.5yo
평균 나이

경험이 풍부한 이사회: BDSX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.2 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/01 12:31
종가2026/05/01 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Biodesix, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Sung Ji NamBTIG
Kyle MiksonCanaccord Genuity
William BonelloCraig-Hallum Capital Group LLC